IQVIA Holdings Inc. $IQV Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 149,626 shares of the medical research company’s stock after selling 7,489 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of IQVIA worth $28,420,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Verdence Capital Advisors LLC acquired a new position in IQVIA in the second quarter valued at approximately $3,612,000. Amundi lifted its stake in shares of IQVIA by 46.3% in the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares during the period. Diversified Trust Co boosted its holdings in IQVIA by 57.2% during the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares in the last quarter. Act Two Investors LLC acquired a new stake in IQVIA during the second quarter valued at $26,528,000. Finally, Oregon Public Employees Retirement Fund increased its holdings in IQVIA by 37.1% in the third quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock valued at $3,697,000 after buying an additional 5,271 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.9%

Shares of IQV opened at $239.15 on Friday. The stock has a 50 day moving average price of $228.82 and a 200 day moving average price of $205.11. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market capitalization of $40.73 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 2.46 and a beta of 1.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IQV shares. Stifel Nicolaus increased their target price on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Morgan Stanley boosted their price objective on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Barclays set a $230.00 target price on IQVIA in a research report on Monday, December 15th. Finally, BMO Capital Markets initiated coverage on shares of IQVIA in a report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $251.06.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.